Indica Labs has signed a non-exclusive partnership with Paige, aimed at integrating Paige’s Diagnostic AI models into Indica’s robust anatomic pathology workflow management software, HALO AP.

This will include Paige’s pan-cancer AI application, which was developed using Paige’s foundation model technology. The collaboration allows for best-of-breed AI-enabled workflows designed to improve laboratory efficiency, diagnostic quality, and patient outcomes.

Through this collaboration, customers of Indica Labs and Paige can look forward to several key benefits. First, there will be seamless integration, allowing HALO AP users to easily execute Paige’s AI applications and view the results directly within the HALO AP image management system. Additionally, the commercial teams of both companies will work together to offer best-of-breed solutions, catering to both new and existing customers.

The partnership is also marked by a strong commitment to quality, ensuring that all integrated products meet the highest standards in technical performance, product support, and regulatory compliance. Finally, the collaboration will drive ongoing innovation, with both companies engaging in co-development across various areas, including pharma services, preclinical research, and translational applications.

"We are excited to work with Indica Labs to make Paige’s powerful AI capabilities available to customers through the HALO AP platform,"  said Peter Hamilton, GM of Diagnostics at Paige.

"We are confident that integrating the technologies that Indica and Paige have developed will provide pathologists with the richest set of capabilities that will drive improvements in cancer diagnostics," Hamilton added.

Steven Hashagen, CEO, Indica Labs said, "This partnership represents a significant step forward in our commitment to delivering innovative solutions that meet the evolving needs of our customers. Paige has been a pioneer in AI for pathology diagnostics, so bringing their tools onto our platform is an exciting opportunity for us and our customers."

The joint efforts will initially focus on developing integrated solutions catering to clinical diagnostics. Integration roll-out is expected within the next few months, and collaboration efforts for the life science segment are to ensue in parallel.